High levels of tumor-infiltrating lymphocytes (TILs) in patients with metastatic HER2 + breast cancer treated with pertuzumab, trastuzumab, and taxane-based chemotherapy as first-line therapy are associated with a better prognosis [92]. This evidence concerns the gene ERBB2 and neoplasm.